For siRNA, mRNA, and circular RNA therapeutics, ACON Pharma targets to pumonary disease area with highly unmet medical needs. The current RNA product pipelines using our proprietary lipid nanoparticle (LNP) inhalation technologies are listed below.

For small molecue drugs, ACON Pharma targets to the multibillion-dollar drug market with high sales, high profit margin, and high growth rate. The current product pipelines using our proprietary or IP protected drug delivery platform technologies are listed below with therapeutical areas and market projections.